53 related articles for article (PubMed ID: 38639402)
1. Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide.
Lowentritt BH; Du S; Rossi C; Muser E; Khilfeh I; Kinkead F; Korsiak J; Lefebvre P; Pilon D; Agarwal N
Future Oncol; 2024 May; ():1-9. PubMed ID: 38861305
[TBL] [Abstract][Full Text] [Related]
2. Real-world study: Impact of multidisciplinary management of apalutamide-associated adverse events in prostate cancer.
Córdoba Sánchez J; Monge-Escartín I; Gil J; Carrera C; Sáez-Peñataro J; Ferrer L; Aversa C; Mellado B; Mases J; Ribal MJ; Alcaraz A; Vilaseca A
Prostate; 2024 Jun; ():. PubMed ID: 38888199
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Apalutamide on Thyroid Function in Prostate Cancer Patients.
Moffatt C; Lechner MG; Angell TE; Shen J; Drakaki A; Acosta GJ; Liang TZ; Tsai K
J Endocr Soc; 2024 May; 8(7):bvae105. PubMed ID: 38854906
[TBL] [Abstract][Full Text] [Related]
4. Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.
Shayegan B; Pouliot F; So A; Fernandes J; Macri J
Can Urol Assoc J; 2017 Jun; 11(6):204-209. PubMed ID: 28652880
[TBL] [Abstract][Full Text] [Related]
5. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
[TBL] [Abstract][Full Text] [Related]
6. [Apalutamide, Erleada®].
Sautois B; Denis C
Rev Med Liege; 2022 Oct; 77(10):609-615. PubMed ID: 36226398
[TBL] [Abstract][Full Text] [Related]
7. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
[TBL] [Abstract][Full Text] [Related]
8. Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practice.
Bögemann M; Facchini G; Bauernhofer T; Cathomas R; Xylinas E; Tombal B
Ir J Med Sci; 2023 Dec; 192(6):2643-2651. PubMed ID: 36944842
[TBL] [Abstract][Full Text] [Related]
9. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
[TBL] [Abstract][Full Text] [Related]
10. A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia.
Marx G; Chowdhury S; Krieger L; Hovey E; Shapiro J; Tran B; Tan TH; Ng S; Woo HH
Asia Pac J Clin Oncol; 2024 Apr; ():. PubMed ID: 38639402
[TBL] [Abstract][Full Text] [Related]
11. Apalutamide: A new agent in the management of prostate cancer.
May MB; Glode AE
J Oncol Pharm Pract; 2019 Dec; 25(8):1968-1978. PubMed ID: 31359832
[TBL] [Abstract][Full Text] [Related]
12. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
Al-Salama ZT
Drugs; 2019 Sep; 79(14):1591-1598. PubMed ID: 31489589
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
